TW202019414A - 生物可利用口服劑型 - Google Patents

生物可利用口服劑型 Download PDF

Info

Publication number
TW202019414A
TW202019414A TW108127793A TW108127793A TW202019414A TW 202019414 A TW202019414 A TW 202019414A TW 108127793 A TW108127793 A TW 108127793A TW 108127793 A TW108127793 A TW 108127793A TW 202019414 A TW202019414 A TW 202019414A
Authority
TW
Taiwan
Prior art keywords
compound
sdi
dose
pharmaceutical composition
samples
Prior art date
Application number
TW108127793A
Other languages
English (en)
Chinese (zh)
Inventor
曼達 V 達利
艾克 納席爾 烏丁
Original Assignee
美商 Ptc 治療公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=67766269&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW202019414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 美商 Ptc 治療公司 filed Critical 美商 Ptc 治療公司
Publication of TW202019414A publication Critical patent/TW202019414A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW108127793A 2018-08-03 2019-08-05 生物可利用口服劑型 TW202019414A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862714182P 2018-08-03 2018-08-03
US62/714,182 2018-08-03

Publications (1)

Publication Number Publication Date
TW202019414A true TW202019414A (zh) 2020-06-01

Family

ID=67766269

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108127793A TW202019414A (zh) 2018-08-03 2019-08-05 生物可利用口服劑型

Country Status (23)

Country Link
US (1) US20210205225A1 (cg-RX-API-DMAC7.html)
EP (1) EP3829544A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021532193A (cg-RX-API-DMAC7.html)
KR (1) KR20210041589A (cg-RX-API-DMAC7.html)
CN (1) CN112752570A (cg-RX-API-DMAC7.html)
AR (1) AR115913A1 (cg-RX-API-DMAC7.html)
AU (1) AU2019316036A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021001859A2 (cg-RX-API-DMAC7.html)
CA (1) CA3107737A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021000271A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021001979A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210093A (cg-RX-API-DMAC7.html)
EA (1) EA202190429A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP21011795A (cg-RX-API-DMAC7.html)
IL (1) IL280471A (cg-RX-API-DMAC7.html)
MX (1) MX2021001364A (cg-RX-API-DMAC7.html)
NI (1) NI202100006A (cg-RX-API-DMAC7.html)
PE (1) PE20211410A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021550237A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202100984VA (cg-RX-API-DMAC7.html)
TN (1) TN2021000021A1 (cg-RX-API-DMAC7.html)
TW (1) TW202019414A (cg-RX-API-DMAC7.html)
WO (1) WO2020028778A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US11458126B2 (en) 2017-08-01 2022-10-04 Ptc Therapeutics, Inc. DHODH inhibitor for use in treating hematologic cancers
CN112028888B (zh) * 2020-09-11 2021-08-20 中国药科大学 一种化合物及其制备方法和用途
WO2023130070A2 (en) 2021-12-31 2023-07-06 Ptc Therapeutics, Inc. Carboline compounds and use thereof
US20220151938A1 (en) * 2022-01-28 2022-05-19 Ptc Therapeutics, Inc. Tablet for use in treating huntington's disease and method of making the same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249799A1 (en) 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US7767689B2 (en) 2004-03-15 2010-08-03 Ptc Therapeutics, Inc. Carboline derivatives useful in the treatment of cancer
US8076353B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Inhibition of VEGF translation
US7601840B2 (en) 2004-03-15 2009-10-13 Ptc Therapeutics, Inc. Carboline derivatives useful in the inhibition of angiogenesis
US20100158858A1 (en) 2007-04-13 2010-06-24 Liangxian Cao Administration of carboline derivatives useful in the treatment of cancer and other diseases
HRP20191104T1 (hr) 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
WO2009100176A2 (en) * 2008-02-07 2009-08-13 Abbott Laboratories Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
WO2010138706A1 (en) * 2009-05-27 2010-12-02 Ptc Therapeutics, Inc. Methods for treating breast cancer
HUE052510T2 (hu) 2009-05-27 2021-05-28 Ptc Therapeutics Inc Módszerek a rák és a nem daganatos állapotok kezelésére
US20180344646A1 (en) * 2015-11-25 2018-12-06 Patheon Development Services Inc. Amorphous dispersion granules and oral dosage forms

Also Published As

Publication number Publication date
KR20210041589A (ko) 2021-04-15
PE20211410A1 (es) 2021-08-02
JP2021532193A (ja) 2021-11-25
SG11202100984VA (en) 2021-02-25
WO2020028778A1 (en) 2020-02-06
CN112752570A (zh) 2021-05-04
IL280471A (en) 2021-03-25
PH12021550237A1 (en) 2021-10-11
TN2021000021A1 (en) 2022-10-03
CA3107737A1 (en) 2020-02-06
EA202190429A1 (ru) 2021-06-15
US20210205225A1 (en) 2021-07-08
EP3829544A1 (en) 2021-06-09
CO2021001979A2 (es) 2021-03-08
MX2021001364A (es) 2021-04-13
CR20210093A (es) 2021-05-28
CL2021000271A1 (es) 2021-08-20
AR115913A1 (es) 2021-03-10
NI202100006A (es) 2021-05-21
BR112021001859A2 (pt) 2021-04-27
ECSP21011795A (es) 2021-03-31
AU2019316036A1 (en) 2021-03-04

Similar Documents

Publication Publication Date Title
JP7627302B2 (ja) パルボシクリブの固形剤形
TWI453203B (zh) 包含bibw2992之新固體醫藥調配劑
US20210205225A1 (en) Bioavailable oral dosage forms
EP3616696B1 (en) Orally administrable enzalutamide-containing pharmaceutical composition
CN102238945A (zh) 药物制剂514
EA028009B1 (ru) Фармацевтическая композиция с улучшенной биодоступностью
TWI382838B (zh) 錠劑及其製造方法
CN110809471A (zh) 治疗特应性皮炎以及提高活性药物成分稳定性的制剂、方法、试剂盒和剂型
CA3146024A1 (en) Coated granule, solid dispersion, and preparation containing vortioxetine hydrobromide for oral taste masking
EP3597179B1 (en) Pharmaceutical dosage forms
EA030982B1 (ru) Твердая галеновая форма с высоким содержанием фексофенадина и способ ее получения
EA042654B1 (ru) Биодоступные пероральные дозированные формы
WO2015199115A1 (ja) 経口投与用医薬組成物
AU2023407370A1 (en) Bezuclastinib formulations
HK40025159B (en) Orally administrable enzalutamide-containing pharmaceutical composition
HK40025159A (en) Orally administrable enzalutamide-containing pharmaceutical composition
HK1152478B (en) Solid pharmaceutical formulations comprising bibw 2992